A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

Exclusion Criteria

• •Wheelchair bound or bedridden
• •Any other auto-immune, rheumatic disease, or overlap syndrome other than sJIA
• •Pregnant or lactating, or intending to become pregnant during study conduct and up to 6 months after the last administration of study drug
• •Any significant concurrent medical or surgical condition which would jeopardize the participant's safety or ability to complete the trial
• •History of significant allergic or infusion reactions to prior TCZ infusion, and/or presence of anti-TCZ antibodies at screening
• •Inborn conditions characterized by a compromised immune system
• •Known Human Immunodeficiency Virus (HIV) infection or other acquired forms of immune compromise
• •History of alcohol, drug, or chemical abuse within 6 months of screening
• •Evidence of serious uncontrolled concomitant diseases, including but not limited to the nervous, renal, hepatic, or endocrine systems
• •Any active acute, subacute, chronic or recurrent bacterial, viral, or systemic fungal infection
• •History of atypical tuberculosis (TB)
• •Active TB requiring treatment within 2 years prior to the screening visit
• •Positive purified protein derivative (PPD) at screening
• •Any major episode of infection requiring hospitalization or treatment during screening or treatment with IV antibiotics completing within 4 weeks of the screening visit or oral antibiotics completing within 2 weeks of the screening visit
• •History of reactivation or new onset of a systemic infection within 2 months of the screening visit
• •Positive for hepatitis B or hepatitis C infection
• •Chronic hepatitis, viral or pulmonary disease
• •Significant cardiac or pulmonary disease
• •History of or current cancer or lymphoma
• •Uncontrolled diabetes mellitus
• •History of or concurrent serious gastrointestinal disorders
• •History of macrophage activation syndrome (MAS) within 3 months prior to screening visit